Cynvenio Biosystems Inc. has signed an agreement giving Thermo Fisher Scientific the right to sell its LiquidBiopsy technology.
Cynvenio is a Westlake Village company specializing in the development of genetic analysis technology. Its LiquidBiopsy system uses rare circulating tumor cells in the bloodstream to diagnose and develop individualized cancer treatments for patients, eliminating the need for a solid tissue biopsy. For now, the technology is used only in medical research, not in regular hospitals or clinics.
Thermo Fisher, in Carlsbad, makes equipment and supplies for life science research and has annual revenues of $17 billion. One product is its Ion Torrent Personal Genome Machine system, which analyzes the genetic makeup of samples for research. By combining Cynvenio’s technology and its Ion Torrent system, Thermo Fisher hopes to deliver a way for researchers to understand a particular cancer within 48 hours using a single blood draw.
“As a company, we are dedicated to facilitating a new era of individualized medicine,” Cynvenio Chief Executive André de Fusco said in a statement. “We see incredible value that our platform and Thermo Fisher’s next generation sequencing workflow can bring to translational researchers.”
Financial details of the agreement were not disclosed.